Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus LMWH for cancer-associated thrombosis
ACTRN12617000331336Phase 2Recruiting
- Sponsor
- South Eastern Sydney and Illawarra Area Health Service
- Start
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) comparing Rivaroxaban with LMWH standard of care (2 arms). Primary endpoint: Combined clinically relevant non-major bleeding and major bleeding. Started Apr 2017; status: recruiting.
02
Drugs
rivaroxabandalteparinenoxaparin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on ACTRN12617000331336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000331336.